التداخل بين إيترافيرين وكيتوكونازول

Therefore, administration of potent enzyme inducers of CYP3A4 with ketoconazole tablets is not recommended.

Coadministration of ketoconazole tablets with potent enzyme inducers of CYP3A4 may decrease the bioavailability of ketoconazole to such an extent that efficacy may be reduced.

Concomitant systemic use of itraconazole or ketoconazole and Etravirine may increase plasma concentrations of etravirine.

Simultaneously, plasma concentrations of itraconazole or ketoconazole may be decreased by Etravirine.

Dose adjustments for itraconazole, ketoconazole or posaconazole may be necessary depending on the other co-administered drugs.

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily.

Antifungals : fluconazole ↑ etravirine ↔ fluconazole Co-administration of etravirine and fluconazole significantly increased etravirine exposures.